Summary
This extension study of the phase 3 PAOLA trial found that pasireotide LAR may be a viable, long-term treatment option for patients with acromegaly that is inadequately controlled with first-generation somatostatin analogues. Biochemical control of growth hormone and normalized insulin-like growth factor 1 continued through extension week 28.
- PAOLA
- NCT01137682
- pasireotide LAR
- octreotide LAR
- lanreotide Autogel
- growth hormone
- acromegaly
- endocrinology
- diabetes & metabolism clinical trials
- hormone therapy
- pituitary gland disorders
- © 2015 SAGE Publications